Skip to main content
. 2022 Mar 28;10(4):786. doi: 10.3390/biomedicines10040786

Figure 3.

Figure 3

lnc-IL7R exhibits strong anti-COPD therapeutic potential. (A) Probit regression-based dose–response plot (left panel) and table (right panel) of the effect of lnc-IL7R expression on COPD probability. Bubble plots show how lnc-IL7R expression stratifies patients according to (B) GOLD-defined COPD severity, and (C) %LAA-950insp-based emphysema severity. (D) Surface plot of the correlation between lnc-IL7R expression, post-BD FEV1/FVC, and predicted FEV1.